DPP4 and COVID-19: Moreover, GLP-1R agonists and DPP4 inhibitors are known to mediate anti-inflammatory effects in human patients, while controlling glucose levels in hospitalized patients (124) Nevertheless, there is no convincing evidence advocating the use of these drugs as replacements for insulin in severely ill COVID-19 patients.